HR positive + MYC amplification
|
HER2 Negative Breast Cancer
|
HR positive + MYC amplification
|
HER2 Negative Breast Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
HR positive + MYC amplification
|
HER2 Negative Breast Cancer
|
HR positive + MYC amplification
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials
|
CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials
|